Condition: Triple-negative Breast Cancer · Sponsor: Fudan University
This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.
This description comes directly from the study's public registry record.
Zhimin Shao, MD, PhD · +8664175590 · zhimingshao@yahoo.com
Yin Liu, MD · +8664175590 · liuyinfudan@163.com
Always discuss trial participation with your own doctor first.
| 270 Dongan Road, Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06355037